SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
Objective: CR1447, a novel transdermal formulation of 4-hydroxytestosterone, has aromatase-inhibiting and androgen receptor (AR)-modulating properties (IC50 4.4 nM) with antitumor effects against AR-positive tumor cells in vitro. This trial investigated the efficacy and safety of CR1447 for patients...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2023-01-01
|
Series: | Endocrine Oncology |
Subjects: | |
Online Access: | https://eo.bioscientifica.com/view/journals/eo/2/1/EO-21-0009.xml |